INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41901, 16989, 'Cyclobenzaprine', 'Anticholinergic Syndrome', 'Cyclobenzaprine has anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with cyclobenzaprine should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Glaucoma should be treated and under control prior to initiation of cyclobenzaprine therapy, and intraocular pressure monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41902, 23013, 'Cyclobenzaprine', 'Anticholinergic Syndrome', 'Cyclobenzaprine has anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with cyclobenzaprine should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Glaucoma should be treated and under control prior to initiation of cyclobenzaprine therapy, and intraocular pressure monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41903, 23014, 'Cyclobenzaprine', 'Anticholinergic Syndrome', 'Cyclobenzaprine has anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with cyclobenzaprine should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Glaucoma should be treated and under control prior to initiation of cyclobenzaprine therapy, and intraocular pressure monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41904, 25264, 'Cyclobenzaprine', 'Anticholinergic Syndrome', 'Cyclobenzaprine has anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with cyclobenzaprine should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Glaucoma should be treated and under control prior to initiation of cyclobenzaprine therapy, and intraocular pressure monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41905, 31131, 'Cyclobenzaprine', 'Anticholinergic Syndrome', 'Cyclobenzaprine has anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with cyclobenzaprine should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Glaucoma should be treated and under control prior to initiation of cyclobenzaprine therapy, and intraocular pressure monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41906, 33230, 'Cyclobenzaprine', 'Anticholinergic Syndrome', 'Cyclobenzaprine has anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with cyclobenzaprine should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Glaucoma should be treated and under control prior to initiation of cyclobenzaprine therapy, and intraocular pressure monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41907, 33437, 'Cyclobenzaprine', 'Anticholinergic Syndrome', 'Cyclobenzaprine has anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with cyclobenzaprine should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Glaucoma should be treated and under control prior to initiation of cyclobenzaprine therapy, and intraocular pressure monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41908, 3243, 'Cyproheptadine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41909, 11631, 'Cyproheptadine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41910, 11632, 'Cyproheptadine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41911, 3243, 'Cyproheptadine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41912, 11631, 'Cyproheptadine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41913, 11632, 'Cyproheptadine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41914, 3243, 'Cyproheptadine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41915, 11631, 'Cyproheptadine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41916, 11632, 'Cyproheptadine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41917, 3243, 'Cyproheptadine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41918, 11631, 'Cyproheptadine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41919, 11632, 'Cyproheptadine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41920, 0, 'Cycloserine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41921, 0, 'Cycloserine', 'Central Nervous System Diseases', 'The use of cycloserine is contraindicated in patients with seizure disorders, depression, severe anxiety, dementia, psychoses, and alcoholism.  Cycloserine is associated with a high incidence of dose-related central nervous system (CNS) toxicities, including confusion, disorientation, aggression, anxiety, psychoses, depression with suicidal tendencies, paresis, seizures, and coma.  CNS effects may be more likely to occur with dosages greater than 500 mg/day, in chronic alcoholics, and during coadministration with ethionamide or isoniazid.  Toxicity correlates with blood levels exceeding 30 mcg/mL.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41922, 0, 'Cycloserine', 'Kidney Diseases', 'The use of cycloserine is contraindicated in patients with severe renal impairment.  Cycloserine is associated with a high incidence of neurotoxicities, which correlates with blood levels exceeding 30 mcg/mL.  Since cycloserine is primarily eliminated by the kidney, patients with renal impairment may be more likely to experience toxicity due to inadequate drug clearance.  Patients with reduced renal function should be monitored closely during therapy with cycloserine.  Blood levels should be drawn weekly, and dosage adjusted accordingly.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41923, 4177, 'Cyclophosphamide', 'Bone Marrow Failure Disorders', 'The use of cyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression which may lead to serious and sometimes fatal infections, including sepsis and septic shock.  Close monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed.  Cyclophosphamide should not be administered to patients with neutrophils <1,500/mm3 and platelets < 50,000/mm3.  Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41924, 4180, 'Cyclophosphamide', 'Bone Marrow Failure Disorders', 'The use of cyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression which may lead to serious and sometimes fatal infections, including sepsis and septic shock.  Close monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed.  Cyclophosphamide should not be administered to patients with neutrophils <1,500/mm3 and platelets < 50,000/mm3.  Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41925, 13766, 'Cyclophosphamide', 'Bone Marrow Failure Disorders', 'The use of cyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression which may lead to serious and sometimes fatal infections, including sepsis and septic shock.  Close monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed.  Cyclophosphamide should not be administered to patients with neutrophils <1,500/mm3 and platelets < 50,000/mm3.  Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41926, 17003, 'Cyclophosphamide', 'Bone Marrow Failure Disorders', 'The use of cyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression which may lead to serious and sometimes fatal infections, including sepsis and septic shock.  Close monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed.  Cyclophosphamide should not be administered to patients with neutrophils <1,500/mm3 and platelets < 50,000/mm3.  Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41927, 17004, 'Cyclophosphamide', 'Bone Marrow Failure Disorders', 'The use of cyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression which may lead to serious and sometimes fatal infections, including sepsis and septic shock.  Close monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed.  Cyclophosphamide should not be administered to patients with neutrophils <1,500/mm3 and platelets < 50,000/mm3.  Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41928, 18313, 'Cyclophosphamide', 'Bone Marrow Failure Disorders', 'The use of cyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression which may lead to serious and sometimes fatal infections, including sepsis and septic shock.  Close monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed.  Cyclophosphamide should not be administered to patients with neutrophils <1,500/mm3 and platelets < 50,000/mm3.  Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41929, 4177, 'Cyclophosphamide', 'Urethral Obstruction', 'The use of cyclophosphamide is contraindicated in patients with any urinary outflow obstruction.  Before treatment initiation, urinary obstruction should be excluded or corrected.  Hemorrhagic cystitis, pyelitis, and hematuria have been reported during cyclophosphamide therapy.  Adequate hydration and use of a prophylactic agent such as mesna prior to each course of cyclophosphamide therapy reduces bladder irritation and hematuria.  Therapy with cyclophosphamide should be administered cautiously in patients with or predisposed to cystitis, including patients with active urinary infections.  Treatment should be discontinued if there is sign of urotoxicity as hemorrhagic cystitis, bladder ulceration, necrosis, fibrosis, contractures, etc.  Urinary sediment should be checked regularly for presence or erythrocytes and other signs of toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41930, 4180, 'Cyclophosphamide', 'Urethral Obstruction', 'The use of cyclophosphamide is contraindicated in patients with any urinary outflow obstruction.  Before treatment initiation, urinary obstruction should be excluded or corrected.  Hemorrhagic cystitis, pyelitis, and hematuria have been reported during cyclophosphamide therapy.  Adequate hydration and use of a prophylactic agent such as mesna prior to each course of cyclophosphamide therapy reduces bladder irritation and hematuria.  Therapy with cyclophosphamide should be administered cautiously in patients with or predisposed to cystitis, including patients with active urinary infections.  Treatment should be discontinued if there is sign of urotoxicity as hemorrhagic cystitis, bladder ulceration, necrosis, fibrosis, contractures, etc.  Urinary sediment should be checked regularly for presence or erythrocytes and other signs of toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41931, 13766, 'Cyclophosphamide', 'Urethral Obstruction', 'The use of cyclophosphamide is contraindicated in patients with any urinary outflow obstruction.  Before treatment initiation, urinary obstruction should be excluded or corrected.  Hemorrhagic cystitis, pyelitis, and hematuria have been reported during cyclophosphamide therapy.  Adequate hydration and use of a prophylactic agent such as mesna prior to each course of cyclophosphamide therapy reduces bladder irritation and hematuria.  Therapy with cyclophosphamide should be administered cautiously in patients with or predisposed to cystitis, including patients with active urinary infections.  Treatment should be discontinued if there is sign of urotoxicity as hemorrhagic cystitis, bladder ulceration, necrosis, fibrosis, contractures, etc.  Urinary sediment should be checked regularly for presence or erythrocytes and other signs of toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41932, 17003, 'Cyclophosphamide', 'Urethral Obstruction', 'The use of cyclophosphamide is contraindicated in patients with any urinary outflow obstruction.  Before treatment initiation, urinary obstruction should be excluded or corrected.  Hemorrhagic cystitis, pyelitis, and hematuria have been reported during cyclophosphamide therapy.  Adequate hydration and use of a prophylactic agent such as mesna prior to each course of cyclophosphamide therapy reduces bladder irritation and hematuria.  Therapy with cyclophosphamide should be administered cautiously in patients with or predisposed to cystitis, including patients with active urinary infections.  Treatment should be discontinued if there is sign of urotoxicity as hemorrhagic cystitis, bladder ulceration, necrosis, fibrosis, contractures, etc.  Urinary sediment should be checked regularly for presence or erythrocytes and other signs of toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41933, 17004, 'Cyclophosphamide', 'Urethral Obstruction', 'The use of cyclophosphamide is contraindicated in patients with any urinary outflow obstruction.  Before treatment initiation, urinary obstruction should be excluded or corrected.  Hemorrhagic cystitis, pyelitis, and hematuria have been reported during cyclophosphamide therapy.  Adequate hydration and use of a prophylactic agent such as mesna prior to each course of cyclophosphamide therapy reduces bladder irritation and hematuria.  Therapy with cyclophosphamide should be administered cautiously in patients with or predisposed to cystitis, including patients with active urinary infections.  Treatment should be discontinued if there is sign of urotoxicity as hemorrhagic cystitis, bladder ulceration, necrosis, fibrosis, contractures, etc.  Urinary sediment should be checked regularly for presence or erythrocytes and other signs of toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41934, 18313, 'Cyclophosphamide', 'Urethral Obstruction', 'The use of cyclophosphamide is contraindicated in patients with any urinary outflow obstruction.  Before treatment initiation, urinary obstruction should be excluded or corrected.  Hemorrhagic cystitis, pyelitis, and hematuria have been reported during cyclophosphamide therapy.  Adequate hydration and use of a prophylactic agent such as mesna prior to each course of cyclophosphamide therapy reduces bladder irritation and hematuria.  Therapy with cyclophosphamide should be administered cautiously in patients with or predisposed to cystitis, including patients with active urinary infections.  Treatment should be discontinued if there is sign of urotoxicity as hemorrhagic cystitis, bladder ulceration, necrosis, fibrosis, contractures, etc.  Urinary sediment should be checked regularly for presence or erythrocytes and other signs of toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41935, 4177, 'Cyclophosphamide', 'Cardiotoxicity', 'Myocarditis, myopericarditis, pericardial effusion including cardiac tamponade, and congestive heart failure, which may be fatal, have been reported with cyclophosphamide therapy.  Supraventricular arrhythmias and ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported after treatment with regimens that included cyclophosphamide.  The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents.Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with preexisting cardiac disease.  These patients should be closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41936, 4180, 'Cyclophosphamide', 'Cardiotoxicity', 'Myocarditis, myopericarditis, pericardial effusion including cardiac tamponade, and congestive heart failure, which may be fatal, have been reported with cyclophosphamide therapy.  Supraventricular arrhythmias and ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported after treatment with regimens that included cyclophosphamide.  The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents.Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with preexisting cardiac disease.  These patients should be closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41937, 13766, 'Cyclophosphamide', 'Cardiotoxicity', 'Myocarditis, myopericarditis, pericardial effusion including cardiac tamponade, and congestive heart failure, which may be fatal, have been reported with cyclophosphamide therapy.  Supraventricular arrhythmias and ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported after treatment with regimens that included cyclophosphamide.  The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents.Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with preexisting cardiac disease.  These patients should be closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41938, 17003, 'Cyclophosphamide', 'Cardiotoxicity', 'Myocarditis, myopericarditis, pericardial effusion including cardiac tamponade, and congestive heart failure, which may be fatal, have been reported with cyclophosphamide therapy.  Supraventricular arrhythmias and ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported after treatment with regimens that included cyclophosphamide.  The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents.Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with preexisting cardiac disease.  These patients should be closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41939, 17004, 'Cyclophosphamide', 'Cardiotoxicity', 'Myocarditis, myopericarditis, pericardial effusion including cardiac tamponade, and congestive heart failure, which may be fatal, have been reported with cyclophosphamide therapy.  Supraventricular arrhythmias and ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported after treatment with regimens that included cyclophosphamide.  The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents.Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with preexisting cardiac disease.  These patients should be closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41940, 18313, 'Cyclophosphamide', 'Cardiotoxicity', 'Myocarditis, myopericarditis, pericardial effusion including cardiac tamponade, and congestive heart failure, which may be fatal, have been reported with cyclophosphamide therapy.  Supraventricular arrhythmias and ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported after treatment with regimens that included cyclophosphamide.  The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents.Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with preexisting cardiac disease.  These patients should be closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41941, 4177, 'Cyclophosphamide', 'Liver Diseases', 'Cyclophosphamide is metabolized by the liver to a biologically active form.  Metabolic activation and therapeutic activity may be altered in patients with hepatic impairment.  Additionally, Veno-occlusive liver disease (VOD) sometimes with fatal outcome has been reported in patients receiving cyclophosphamide- containing regimens.  VOD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide.  Preexisting disturbances of hepatic function seems to also be a risk factor.  Therapy with cyclophosphamide should be administered cautiously in patients with compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41942, 4180, 'Cyclophosphamide', 'Liver Diseases', 'Cyclophosphamide is metabolized by the liver to a biologically active form.  Metabolic activation and therapeutic activity may be altered in patients with hepatic impairment.  Additionally, Veno-occlusive liver disease (VOD) sometimes with fatal outcome has been reported in patients receiving cyclophosphamide- containing regimens.  VOD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide.  Preexisting disturbances of hepatic function seems to also be a risk factor.  Therapy with cyclophosphamide should be administered cautiously in patients with compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41943, 13766, 'Cyclophosphamide', 'Liver Diseases', 'Cyclophosphamide is metabolized by the liver to a biologically active form.  Metabolic activation and therapeutic activity may be altered in patients with hepatic impairment.  Additionally, Veno-occlusive liver disease (VOD) sometimes with fatal outcome has been reported in patients receiving cyclophosphamide- containing regimens.  VOD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide.  Preexisting disturbances of hepatic function seems to also be a risk factor.  Therapy with cyclophosphamide should be administered cautiously in patients with compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41944, 17003, 'Cyclophosphamide', 'Liver Diseases', 'Cyclophosphamide is metabolized by the liver to a biologically active form.  Metabolic activation and therapeutic activity may be altered in patients with hepatic impairment.  Additionally, Veno-occlusive liver disease (VOD) sometimes with fatal outcome has been reported in patients receiving cyclophosphamide- containing regimens.  VOD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide.  Preexisting disturbances of hepatic function seems to also be a risk factor.  Therapy with cyclophosphamide should be administered cautiously in patients with compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41945, 17004, 'Cyclophosphamide', 'Liver Diseases', 'Cyclophosphamide is metabolized by the liver to a biologically active form.  Metabolic activation and therapeutic activity may be altered in patients with hepatic impairment.  Additionally, Veno-occlusive liver disease (VOD) sometimes with fatal outcome has been reported in patients receiving cyclophosphamide- containing regimens.  VOD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide.  Preexisting disturbances of hepatic function seems to also be a risk factor.  Therapy with cyclophosphamide should be administered cautiously in patients with compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41946, 18313, 'Cyclophosphamide', 'Liver Diseases', 'Cyclophosphamide is metabolized by the liver to a biologically active form.  Metabolic activation and therapeutic activity may be altered in patients with hepatic impairment.  Additionally, Veno-occlusive liver disease (VOD) sometimes with fatal outcome has been reported in patients receiving cyclophosphamide- containing regimens.  VOD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide.  Preexisting disturbances of hepatic function seems to also be a risk factor.  Therapy with cyclophosphamide should be administered cautiously in patients with compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41947, 4177, 'Cyclophosphamide', 'Lung Diseases', 'Pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to respiratory failure have been reported during and following treatment with cyclophosphamide.  Pneumonitis may develop years after treatment with cyclophosphamide.  Patients should be monitored for signs and symptoms of pulmonary toxicity.  Caution is advised in patients with preexisting pulmonary impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41948, 4180, 'Cyclophosphamide', 'Lung Diseases', 'Pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to respiratory failure have been reported during and following treatment with cyclophosphamide.  Pneumonitis may develop years after treatment with cyclophosphamide.  Patients should be monitored for signs and symptoms of pulmonary toxicity.  Caution is advised in patients with preexisting pulmonary impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41949, 13766, 'Cyclophosphamide', 'Lung Diseases', 'Pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to respiratory failure have been reported during and following treatment with cyclophosphamide.  Pneumonitis may develop years after treatment with cyclophosphamide.  Patients should be monitored for signs and symptoms of pulmonary toxicity.  Caution is advised in patients with preexisting pulmonary impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41950, 17003, 'Cyclophosphamide', 'Lung Diseases', 'Pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to respiratory failure have been reported during and following treatment with cyclophosphamide.  Pneumonitis may develop years after treatment with cyclophosphamide.  Patients should be monitored for signs and symptoms of pulmonary toxicity.  Caution is advised in patients with preexisting pulmonary impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41951, 17004, 'Cyclophosphamide', 'Lung Diseases', 'Pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to respiratory failure have been reported during and following treatment with cyclophosphamide.  Pneumonitis may develop years after treatment with cyclophosphamide.  Patients should be monitored for signs and symptoms of pulmonary toxicity.  Caution is advised in patients with preexisting pulmonary impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41952, 18313, 'Cyclophosphamide', 'Lung Diseases', 'Pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to respiratory failure have been reported during and following treatment with cyclophosphamide.  Pneumonitis may develop years after treatment with cyclophosphamide.  Patients should be monitored for signs and symptoms of pulmonary toxicity.  Caution is advised in patients with preexisting pulmonary impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41953, 4177, 'Cyclophosphamide', 'Kidney Diseases', 'In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites, which may result in increased toxicity.  Monitor patients with severe renal impairment (CrCl =10 mL/min to 24 mL/min) for signs and symptoms of toxicity.  Therapy with cyclophosphamide should be administered cautiously in patients with a history of or predisposition to renal dysfunction.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41954, 4180, 'Cyclophosphamide', 'Kidney Diseases', 'In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites, which may result in increased toxicity.  Monitor patients with severe renal impairment (CrCl =10 mL/min to 24 mL/min) for signs and symptoms of toxicity.  Therapy with cyclophosphamide should be administered cautiously in patients with a history of or predisposition to renal dysfunction.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41955, 13766, 'Cyclophosphamide', 'Kidney Diseases', 'In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites, which may result in increased toxicity.  Monitor patients with severe renal impairment (CrCl =10 mL/min to 24 mL/min) for signs and symptoms of toxicity.  Therapy with cyclophosphamide should be administered cautiously in patients with a history of or predisposition to renal dysfunction.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41956, 17003, 'Cyclophosphamide', 'Kidney Diseases', 'In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites, which may result in increased toxicity.  Monitor patients with severe renal impairment (CrCl =10 mL/min to 24 mL/min) for signs and symptoms of toxicity.  Therapy with cyclophosphamide should be administered cautiously in patients with a history of or predisposition to renal dysfunction.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41957, 17004, 'Cyclophosphamide', 'Kidney Diseases', 'In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites, which may result in increased toxicity.  Monitor patients with severe renal impairment (CrCl =10 mL/min to 24 mL/min) for signs and symptoms of toxicity.  Therapy with cyclophosphamide should be administered cautiously in patients with a history of or predisposition to renal dysfunction.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41958, 18313, 'Cyclophosphamide', 'Kidney Diseases', 'In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites, which may result in increased toxicity.  Monitor patients with severe renal impairment (CrCl =10 mL/min to 24 mL/min) for signs and symptoms of toxicity.  Therapy with cyclophosphamide should be administered cautiously in patients with a history of or predisposition to renal dysfunction.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41959, 1235, 'Cyanocobalamin', 'Hypokalemia', 'Hypokalemia (resulting in death) has occurred during vitamin B12 therapy as a result of increased red blood cell requirements during hematopoiesis.  Clinical monitoring and correction of potassium levels prior to and during vitamin B12 therapy is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41960, 7400, 'Cyanocobalamin', 'Hypokalemia', 'Hypokalemia (resulting in death) has occurred during vitamin B12 therapy as a result of increased red blood cell requirements during hematopoiesis.  Clinical monitoring and correction of potassium levels prior to and during vitamin B12 therapy is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41961, 20830, 'Cyanocobalamin', 'Hypokalemia', 'Hypokalemia (resulting in death) has occurred during vitamin B12 therapy as a result of increased red blood cell requirements during hematopoiesis.  Clinical monitoring and correction of potassium levels prior to and during vitamin B12 therapy is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41962, 32091, 'Cyanocobalamin', 'Hypokalemia', 'Hypokalemia (resulting in death) has occurred during vitamin B12 therapy as a result of increased red blood cell requirements during hematopoiesis.  Clinical monitoring and correction of potassium levels prior to and during vitamin B12 therapy is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41963, 1235, 'Cyanocobalamin', 'Optic Atrophy, Hereditary, Leber', 'The use of cyanocobalamin is contraindicated in patients with Leber''s disease (hereditary optic nerve atrophy).  Cyanocobalamin has induced severe and rapid optic nerve atrophy in patient''s with early Leber''s disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41964, 7400, 'Cyanocobalamin', 'Optic Atrophy, Hereditary, Leber', 'The use of cyanocobalamin is contraindicated in patients with Leber''s disease (hereditary optic nerve atrophy).  Cyanocobalamin has induced severe and rapid optic nerve atrophy in patient''s with early Leber''s disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41965, 20830, 'Cyanocobalamin', 'Optic Atrophy, Hereditary, Leber', 'The use of cyanocobalamin is contraindicated in patients with Leber''s disease (hereditary optic nerve atrophy).  Cyanocobalamin has induced severe and rapid optic nerve atrophy in patient''s with early Leber''s disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41966, 32091, 'Cyanocobalamin', 'Optic Atrophy, Hereditary, Leber', 'The use of cyanocobalamin is contraindicated in patients with Leber''s disease (hereditary optic nerve atrophy).  Cyanocobalamin has induced severe and rapid optic nerve atrophy in patient''s with early Leber''s disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41967, 1235, 'Cyanocobalamin', 'Malabsorption Syndromes', 'Absorption of vitamin B12 is decreased in malabsorption syndromes and in pernicious anemia without coadministration of intrinsic factor (IF).  Cyanocobalamin is rapidly absorbed following IM or subcutaneous injections.  Hydroxocobalamin (cyanocobalamin analog) functions the same a cyanocobalamin, but has induced antibody formation to the hydroxocobalamin-transcobalamin II complex.  The use of cyanocobalamin may be preferred in patients with these conditions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41968, 7400, 'Cyanocobalamin', 'Malabsorption Syndromes', 'Absorption of vitamin B12 is decreased in malabsorption syndromes and in pernicious anemia without coadministration of intrinsic factor (IF).  Cyanocobalamin is rapidly absorbed following IM or subcutaneous injections.  Hydroxocobalamin (cyanocobalamin analog) functions the same a cyanocobalamin, but has induced antibody formation to the hydroxocobalamin-transcobalamin II complex.  The use of cyanocobalamin may be preferred in patients with these conditions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41969, 20830, 'Cyanocobalamin', 'Malabsorption Syndromes', 'Absorption of vitamin B12 is decreased in malabsorption syndromes and in pernicious anemia without coadministration of intrinsic factor (IF).  Cyanocobalamin is rapidly absorbed following IM or subcutaneous injections.  Hydroxocobalamin (cyanocobalamin analog) functions the same a cyanocobalamin, but has induced antibody formation to the hydroxocobalamin-transcobalamin II complex.  The use of cyanocobalamin may be preferred in patients with these conditions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41970, 32091, 'Cyanocobalamin', 'Malabsorption Syndromes', 'Absorption of vitamin B12 is decreased in malabsorption syndromes and in pernicious anemia without coadministration of intrinsic factor (IF).  Cyanocobalamin is rapidly absorbed following IM or subcutaneous injections.  Hydroxocobalamin (cyanocobalamin analog) functions the same a cyanocobalamin, but has induced antibody formation to the hydroxocobalamin-transcobalamin II complex.  The use of cyanocobalamin may be preferred in patients with these conditions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41971, 1235, 'Cyanocobalamin', 'Kidney Diseases', 'Cyanocobalamin products contain aluminum that may be toxic and may reach toxic levels with prolonged parenteral administration if kidney function is impaired.  Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and other solutions which also contain aluminum.  Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum greater than 4-5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity.  Caution and monitoring are recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41972, 7400, 'Cyanocobalamin', 'Kidney Diseases', 'Cyanocobalamin products contain aluminum that may be toxic and may reach toxic levels with prolonged parenteral administration if kidney function is impaired.  Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and other solutions which also contain aluminum.  Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum greater than 4-5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity.  Caution and monitoring are recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41973, 20830, 'Cyanocobalamin', 'Kidney Diseases', 'Cyanocobalamin products contain aluminum that may be toxic and may reach toxic levels with prolonged parenteral administration if kidney function is impaired.  Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and other solutions which also contain aluminum.  Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum greater than 4-5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity.  Caution and monitoring are recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41974, 32091, 'Cyanocobalamin', 'Kidney Diseases', 'Cyanocobalamin products contain aluminum that may be toxic and may reach toxic levels with prolonged parenteral administration if kidney function is impaired.  Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and other solutions which also contain aluminum.  Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum greater than 4-5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity.  Caution and monitoring are recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41975, 14350, 'Cytarabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41976, 17025, 'Cytarabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41977, 17026, 'Cytarabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41978, 17027, 'Cytarabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41979, 17028, 'Cytarabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41980, 17029, 'Cytarabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41981, 17030, 'Cytarabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41982, 27849, 'Cytarabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41983, 27850, 'Cytarabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41984, 27851, 'Cytarabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41985, 27852, 'Cytarabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41986, 14350, 'Cytarabine', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41987, 17025, 'Cytarabine', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41988, 17026, 'Cytarabine', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41989, 17027, 'Cytarabine', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41990, 17028, 'Cytarabine', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41991, 17029, 'Cytarabine', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41992, 17030, 'Cytarabine', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41993, 27849, 'Cytarabine', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41994, 27850, 'Cytarabine', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41995, 27851, 'Cytarabine', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41996, 27852, 'Cytarabine', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41997, 14350, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41998, 17025, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41999, 17026, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42000, 17027, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '', 'DDInter', 0);
